Logotype for Teladoc Health Inc

Teladoc Health (TDOC) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Teladoc Health Inc

Q1 2026 earnings summary

30 Apr, 2026

Executive summary

  • Q1 2026 revenue was $614 million, down 2% year-over-year, with net loss narrowing to $63.8 million from $93.0 million in the prior year; Adjusted EBITDA was $58.2 million, flat year-over-year, and results exceeded guidance midpoints.

  • Integrated Care revenue grew 2% to $395.4 million, while BetterHelp revenue declined 9% to $218.4 million, reflecting visit-based revenue growth and international expansion in Integrated Care and cash pay pressure in BetterHelp.

  • Strategic focus on product innovation, AI integration, and expanding insurance coverage in BetterHelp, with insurance now live in 30 states and DC, and over 6,000 credentialed providers.

  • Operational excellence and cost discipline remain priorities, with AI-driven efficiencies and a strong balance sheet supporting ongoing investments.

Financial highlights

  • Q1 2026 consolidated revenue: $614 million; Adjusted EBITDA: $58.2 million (9.5% margin); net loss per share: $0.36, including $0.50 amortization, $0.08 stock-based compensation, and $0.07 restructuring costs per share.

  • Free cash flow: net outflow of $26.3 million; cash and equivalents: $751 million; convertible senior notes: $996 million; net debt to trailing Adjusted EBITDA: under 0.9x.

  • U.S. revenue for Q1 2026 was $491.5–$525 million; international revenue was $89–$122.3 million.

  • Advertising and marketing expenses decreased 10% to $151.5 million; general and administrative expenses fell 9% to $102.1 million.

  • Amortization of intangible assets increased 7% to $89.8 million, driven by accelerated amortization from brand transition.

Outlook and guidance

  • 2026 consolidated revenue guidance: $2.48–$2.58 billion; Adjusted EBITDA: $267–$306 million; free cash flow: $130–$170 million.

  • Full-year net loss per share projected at $1.05–$0.75; stock-based compensation expected below $55 million (down 30% YoY).

  • Q2 2026 revenue guidance: $597–$626 million; Adjusted EBITDA: $55–$67 million.

  • Integrated Care 2026 Adjusted EBITDA margin guidance: 15.1%–16.1%; BetterHelp revenue guidance narrowed to down 6.5% to down 1.0% YoY, with insurance revenue expected at $90–$105 million.

  • Pre-tax restructuring costs for 2026 expected to remain within $15–$20 million.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more